beta-Alanine Concept

subject area of

• 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Journal Articles
• A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery  Journal Articles
• Activated prothrombin complex concentrate for dabigatran‐associated bleeding  Journal Articles
• Acute management of bleeding in patients on novel oral anticoagulants  Journal Articles
• Additional Events in the RE-LY Trial  Journal Articles
• Adherence to anticoagulant treatment with dabigatran in a real‐world setting  Journal Articles
• Advantages and limitations of the new anticoagulants  Journal Articles
• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer  Journal Articles
• Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer  Journal Articles
• Antithrombotic Therapy for Atrial Fibrillation  Journal Articles
• Approach to the new oral anticoagulants in family practice: part 1: comparing the options.  Journal Articles
• Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.  Journal Articles
• Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation  Journal Articles
• Bleeding and antidotes in new oral anticoagulants  Journal Articles
• Carnosine, taurine and enzyme activities of human skeletal muscle fibres from elderly subjects with osteoarthritis and young moderately active subjects  Journal Articles
• Causes of Death and Influencing Factors in Patients With Atrial Fibrillation  Journal Articles
• Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications  Journal Articles
• Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?  Journal Articles
• Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation  Journal Articles
• Dabigatran Versus Warfarin in Patients With Atrial Fibrillation  Journal Articles
• Dabigatran and risk of myocardial infarction  Journal Articles
• Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management  Journal Articles
• Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?  Journal Articles
• Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‐LY trial  Journal Articles
• Dabigatran efficacy‐safety assessment for stroke prevention in patients with atrial fibrillation  Journal Articles
• Dabigatran for patients with a mechanical valve  Journal Articles
• Dabigatran in Patients with Mechanical Heart Valves  Journal Articles
• Dabigatran monitoring made simple?  Journal Articles
• Dabigatran versus Warfarin in Patients with Mechanical Heart Valves  Journal Articles
• Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada  Journal Articles
• Dabigatran versus warfarin in patients with mechanical heart valves: reply  Journal Articles
• Dabigatran-Induced Acute Hepatitis  Journal Articles
• Dabigatran-related coagulopathy: when can we assume the effect has “worn off”?  Journal Articles
• Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation  Journal Articles
• Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation  Journal Articles
• Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial -  Journal Articles
• Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty  Journal Articles
• Evolving use of new oral anticoagulants for treatment of venous thromboembolism  Journal Articles
• Extended Anticoagulation in Venous Thromboembolism  Journal Articles
• Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism  Journal Articles
• Extended anticoagulation in venous thromboembolism.  Journal Articles
• Extended anticoagulation in venous thromboembolism.  Journal Articles
• Extended anticoagulation in venous thromboembolism.  Journal Articles
• Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies  Journal Articles
• Home-monitoring of oral anticoagulation vs. dabigatran  Journal Articles
• How I treat target-specific oral anticoagulant–associated bleeding  Journal Articles
• Idarucizumab for Dabigatran Reversal  Journal Articles
• Intensity and Quality of Warfarin Anticoagulation in Chinese Patients  Journal Articles
• Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran  Journal Articles
• Is there a role for the novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials  Journal Articles
• Is there really misuse and abuse of dabigatran?  Journal Articles
• Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants  Journal Articles
• Letter by Van de Werf et al Regarding Article, “Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians”  Journal Articles
• Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin  Journal Articles
• Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor  Journal Articles
• Management of Anticoagulation Around Pacemaker and Defibrillator Surgery  Journal Articles
• Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting  Journal Articles
• More on Acutely Injured Patients Receiving Dabigatran  Journal Articles
• Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial  Journal Articles
• New anticoagulants in atrial fibrillation management  Conferences
• New oral anticoagulant agents – general features and outcomes in subsets of patients  Journal Articles
• New oral anticoagulants and oculoplastic surgery  Journal Articles
• New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions  Journal Articles
• New oral anticoagulants: which one should my patient use?  Journal Articles
• Novel oral anticoagulants in secondary prevention of stroke  Journal Articles
• Nutritional Strategies to Support Adaptation to High-Intensity Interval Training in Team Sports  Journal Articles
• Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits  Journal Articles
• Overview of the New Oral Anticoagulants  Journal Articles
• Patient outcomes using the European label for dabigatran  Journal Articles
• Perioperative Management of Dabigatran  Journal Articles
• Perioperative management of patients who are receiving a novel oral anticoagulant  Journal Articles
• Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin  Journal Articles
• Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran  Journal Articles
• Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy  Journal Articles
• Pharmacogenetics of Antiplatelets and Anticoagulants: A Report on Clopidogrel, Warfarin and Dabigatran  Journal Articles
• Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management  Journal Articles
• Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation  Journal Articles
• Practical aspects of new oral anticoagulant use in atrial fibrillation  Journal Articles
• Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban  Journal Articles
• Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran  Journal Articles
• Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding  Journal Articles
• Response to Letter Regarding Article, “Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study”  Journal Articles
• Response to Letter Regarding Article, “Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis”  Journal Articles
• Response to Letter Regarding Article, “Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin”  Journal Articles
• Response to Letters Regarding Article, “Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”  Journal Articles
• Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.  Journal Articles
• Response.  Journal Articles
• Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit)  Journal Articles
• Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation  Journal Articles
• Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS_2 Score: A Subgroup Analysis of the RE-LY Trial  Journal Articles
• Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysis  Journal Articles
• Stroke Prevention in Atrial Fibrillation Patients With Chronic Kidney Disease  Journal Articles
• The Effects of Beta-Alanine Supplementation on Performance: A Systematic Review of the Literature  Journal Articles
• The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?  Journal Articles
• The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study  Journal Articles
• The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses  Journal Articles
• Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding  Journal Articles
• Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis  Journal Articles
• Treatment of venous thromboembolism with dabigatran  Journal Articles
• Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.  Journal Articles
• Venous thromboembolism management: where do novel anticoagulants fit?  Journal Articles
• Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin  Journal Articles
• Well-managed warfarin is superior to NOACs Response  Journal Articles
• β-Alanine Supplementation Does Not Augment the Skeletal Muscle Adaptive Response to 6 Weeks of Sprint Interval Training  Journal Articles
• γT‐S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo  Journal Articles